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Predicting Factors for Death from Other Causes in Patients with 
Localized Renal Cell Carcinoma
Jin Suk Chang, Yong Hyun Park, Ja Hyun Ku, Cheol Kwak, Hyeon Hoe Kim
Department of Urology, Seoul National University College of Medicine, Seoul, Korea
Purpose: To identify the predictors of death from other causes in patients with localized 
renal cell carcinoma (RCC).
Materials and Methods: We identified 1,101 patients with pathologically confirmed T1 
or T2 RCC with a follow-up duration of over 6 months. Survival according to the cause 
of death was evaluated by using the Kaplan-Meier analysis with log-rank test. 
Prognostic factors for death from other causes were assessed by multivariate analysis 
using the Cox proportional hazard regression model. Once the prognostic factors were 
identified, a risk-group variable was created by counting the number of unfavorable 
features present for each patient.
Results: The median follow-up was 62 months, and RCC-related death occurred in 50 
patients (4.5%), whereas death from other causes occurred in 47 (4.3%). Patients who 
died from other causes had a higher American Society of Anesthesiologist (ASA) score 
(26.1% vs. 10.2%; p=0.044), older age (63.4 years vs. 55.0 years; p＜0.001), smaller mass 
size (5.1 cm vs. 7.9 cm; p＜0.001), and lower nuclear grade (p=0.003). In the multivariate 
Cox regression analysis, older age, higher ASA score, and lower body mass index were 
independent factors predicting death from other causes in patients with localized RCC. 
On the basis of the number of risk factors for death from other causes, the 5-year oth-
er-cause-specific survival was 98.3% (0 risk factors), 84.7% (1 risk factor), and 67.6% 
(2 or 3 risk factors), respectively (p＜0.001).
Conclusions: Older age, higher ASA score, and lower body mass index were independent 
predictors of death from other causes in patients with localized RCC.
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INTRODUCTION
Over the past three decades, there has been a gradual in-
crease in the incidence of renal cell carcinoma (RCC), co-
inciding with the widespread use of routine abdominal 
imaging [1]. However, despite an increase in early de-
tection, overall death rates have not decreased, which sug-
gests that treatment of these incidental renal masses may 
be of little or no benefit to some patients. Thus, the standard 
of care for localized RCC now includes active surveillance 
in selected patients with comorbidities or limited life 
expectancy. Several studies converging to support active 
surveillance have shown growth rates of approximately 
0.28 cm per year [2], with only 1% progression to metastatic 
disease for patients undergoing active surveillance [3]. 
Given the natural history of localized RCC, the long-term 
beneﬁt of aggressive treatment might depend in large part 
on competing risks of death. Thus, further analysis of mor-
tality and cause of death is important to identify the risk 
factors for death following curative surgery for localized 
RCC. To address these unresolved issues, we evaluated the 
relationship between RCC and the risk of death and pre-
dictors of death from other causes in patients with localized 
RCC. Korean J Urol 2012;53:18-22
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FIG. 1. Cumulative incidence of death by cause (RCC vs. other 
cause).
TABLE 1. Clinical characteristics of the patients according to 
cause of death
Characteristic Other cause RCC p-value
Age (yr)
Gender 
Male
Female
BMI (kg/m
2)
ASA score 
1-2
3-4
Symptom at diagnosis 
Laterality 
Right
Left
Surgical method 
Radical nephrectomy
Partial nephrectomy
63.4 (±9.9)
   38 (80.9)
     9 (19.1)
23.5 (±3.6)
   34 (72.3)
   12 (25.5)
   28 (59.6)
   26 (55.3)
   21 (44.7)
   42 (89.4)
     5 (10.6)
55.0 (±10.9)
   33 (66.0)
   17 (34.0)
23.7 (±3.3)
   44 (88.0)
     5 (10.0)
   38 (76.0)
   15 (30.0)
   35 (70.0)
   48 (96.0)
     2 (4.0)
＜0.001
0.099
0.776
0.044
0.083
0.014
0.426
Value are presented as mean±standard deviation or number (%). 
RCC, renal cell carcinoma; BMI, body mass index; ASA, American 
Society of Anesthesiologist.
MATERIALS AND METHODS
From 1989 to 2009, 1,101 consecutive patients with patho-
logically confirmed T1 or T2 RCC with a duration of fol-
low-up of over 6 months were included in this study. 
Patients with lymph node or distant metastasis, multifocal 
tumors, or Von Hippel-Lindau disease were excluded. 
After approval by the Institutional Review Board at Seoul 
National University Hospital, clinical and pathological da-
ta from eligible patients were retrieved from the medical 
records and reviewed retrospectively.
Patient demographics including age, gender, body mass 
index (BMI), American Society of Anesthesiologist (ASA) 
score, symptoms at initial presentation, and type of sur-
gery (radical nephrectomy or nephron-sparing surgery) 
were evaluated. Patients were categorized according to 
BMI based on the Asia-Pacific criteria for obesity as under-
weight (＜18.5 kg/m
2), normal weight (18.5 to 22.9 kg/m
2), 
overweight (23 to 24.9 kg/m
2), and obese (≥25 kg/m
2) [4]. 
Histologic subtype was determined according to the Union 
for International Cancer Control/American Joint Commi-
ttee on Cancer and Heidelberg recommendations [5], and 
tumor nuclear grade was determined according to the 
Fuhrman system [6]. The database of the Korea National 
Statistical Office was used to determine patient survival 
and cause of death if the patient was lost to follow-up.
Differences in demographics and clinical and patho-
logical factors were examined by using the Student’s t-test 
and chi-square test for continuous and categorical varia-
bles, respectively. Survival according to the cause of death 
was evaluated by Kaplan-Meier analysis with log-rank 
test, and prognostic factors for death from other causes 
were assessed by multivariate analysis with the Cox pro-
portional hazard regression model in a forward stepwise 
regression. Once the prognostic factors were identified, a 
risk-group variable was created by counting the number of 
unfavorable features presented for each patient. Survival 
curves for each of these groups were estimated, and the 
groups were compared by using the log-rank test. All stat-
istical analyses were performed with the use of the stat-
istical software SPSS ver. 17.0 (SPSS Inc., Chicago, IL, 
USA), and p＜0.05 (two sided) was considered statistically 
significant.
RESULTS
The median follow-up for 1,101 patients was 62 months 
(range, 7 to 243 months). At last contact, of the 1,101 pa-
tients, 1,004 (91.2%) were alive, 50 (4.5%) had died from 
RCC, and 47 (4.3%) had died from other causes. Other caus-
es of death included cardiovascular disease, cerebrovas-
cular disease, pulmonary disease, and other malignancies. 
The cumulative incidence of cancer-specific mortality was 
0.4% at 1 year, 2.4% at 3 years, 4.4% at 5 years, and 8.9% 
at 10 years (Fig. 1). Most of the death from RCC occurred 
in the first 10 years following curative surgery, whereas the 
cumulative incidence of death from other causes increased 
steadily over time.
Table 1 lists the characteristics of the patients who died 
from RCC or other causes. The two groups differed with re-
spect to age at operation, ASA score, and laterality. 
Patients who died from other causes were older (63.4 years 
vs. 55.0 years; p＜0.001) and had a higher ASA score (26.1% 
vs. 10.2%; p=0.044) than did those who died from RCC. 
Table 2 shows the pathologic outcomes according to the 
cause of death. Pathologic T stage was significantly higher 
in patients who died from RCC: 56.0% of the patients who 
died from RCC had a score of pT2a or higher, compared with 
14.9% of those who died from other causes (p＜0.001). 
Likewise, a lower nuclear grade, smaller tumor size, and 
presence of tumor necrosis all favored death from other 
causes.
Kaplan-Meier curves demonstrated that other-cau-Korean J Urol 2012;53:18-22
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TABLE 2. Pathologic outcomes of the patients according to cause 
of death
Variable Other cause RCC p-value
T stage 
T1a
T1b
T2a
T2b
Histologic subtype 
Clear cell
Chromophobe
Papillary
Unclassified
Fuhrman’s nuclear grade 
1
2
3
4
Tumor size (cm)
Tumor necrosis 
 22 (46.8)
 18 (38.3)
   4 (8.5)
   3 (6.4)
 42 (93.3)
   1 (2.2)
   1 (2.2)
   1 (2.2)
   3 (6.7)
 24 (53.3)
 18 (40.0)
   0 (0)
5.1 (±3.1)
 16 (57.1)
   5 (10.0)
 17 (34.0)
 18 (36.0)
 10 (20.0)
 40 (85.1)
   2 (4.3)
   3 (6.4)
   2 (4.3)
   2 (4.3)
 11 (23.4)
 27 (57.4)
   7 (16.1)
7.9 (±3.2)
 30 (81.1)
＜0.001
0.643
0.003
＜0.001
0.054
Values are presented as number (%) or mean±standard deviation. 
RCC, renal cell carcinoma.
FIG. 2. Other-cause-specific survival according to (A) age at 
diagnosis, (B) BMI, and (C) ASA score.
se-specific survival differed according to the age at diag-
nosis, BMI, and ASA score (Fig. 2). The unadjusted Kap-
lan-Meier estimates of other-cause-specific survival at 5 
years was 99.3% for patients aged younger than 50 years, 
97.1% for those between 50 and 60 years, 93.2% for those 
between 60 and 70 years, and 82.8% for those older than 
70 years (p＜0.001). With regard to BMI, 5 year oth-
er-cause-specific survival was 77.6% for patients who were 
underweight, 96.4% for those with a normal BMI, 99.3% 
for those who were overweight, and 96.5% for those who 
were obese (p＜0.001). Also, 5 year other-cause-specific 
survival was 97.8% for patients with an ASA score of l or 
2 and 80.1% for those with an ASA score of 3 or higher (p
＜0.001). Competing risks regression showed that age at 
diagnosis, BMI, and ASA score were all significantly asso-
ciated with other-cause-specific death in both univariate 
and multivariate models (Table 3). Based on the number 
of risk factors for death from other causes, 5 year oth-
er-cause-specific survival was 98.3% (0 risk factors), 84.7% 
(1 risk factor), and 67.6% (2 or 3 risk factors), respectively 
(p＜0.001) (Fig. 3).
DISCUSSION
Current options for the management of localized RCC in-
clude surgical excision, thermal ablation, and active Korean J Urol 2012;53:18-22
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TABLE 3. Univariate and multivariate analysis of factors predicting non-cancer-related death
Factor
Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Age (yr)
    ＜50
    50-60
    60-70
    ≥70
BMI (kg/m
2)
    Underweight (＜18.5)
    Normal (18.5-23.0)
    Overweight (23.0-25.0)
    Obesity (≥25.0)
ASA score
    1-2
    3-4
-
  3.794
  7.461
27.211
-
  0.198
  0.107
  0.203
-
  5.091
-
  1.376-10.459
  2.633-21.146
  9.543-77.596
-
0.074-0.528
0.036-0.319
0.079-0.519
-
  2.438-10.634
-
0.010
＜0.001
＜0.001
-
0.001
＜0.001
0.001
-
＜0.001
-
  4.418
  5.994
29.160
-
  0.222
  0.110
  0.156
-
  3.261
-
  1.340-12.836
  1.809-19.859
  8.958-94.925
-
0.082-0.595
0.036-0.329
0.060-0.405
-
1.500-7.093
-
0.014
0.003
＜0.001
-
0.003
＜0.001
＜0.001
-
0.003
HR, hazard ratio; CI, confidence interval; BMI, body mass index; ASA, American Society of Anesthesiologist.
FIG. 3. Other-cause-specific survival according to the number of 
risk factors.
surveillance. A recent meta-analysis failed to demonstrate 
a significant difference in metastasis-free survival be-
tween treatment options over a mean follow-up of 47.1 
months [7]. Not only predicting the behavior of localized 
RCC but also understanding the individual’s competing 
risks of death is especially important in elderly patients 
with comorbidities in whom surgery poses signiﬁcant 
risks. Thus, we examined the patterns of death among pa-
tients with localized RCC. In this study population, 4.5% 
of the patients died from RCC and 4.3% died from other 
causes during the follow-up period. Cancer-specific death 
tended to occur in the first 10 years after curative surgery. 
Conversely, other causes of death that could be attributed 
to age or comorbid conditions steadily increased with time. 
Our data support that when deciding on the treatment 
plans for localized RCC, patients with old age and co-
morbidities and their clinicians must weigh the risk of 
treating localized RCC, which may not affect life expect-
ancy, with the possibility of treating an aggressive RCC 
early.
Several studies have attempted to quantitate the com-
peting risk of death for patients with RCC. Santos et al. [8] 
performed a competing risk analysis in 192 patients with 
clear cell RCC. After a median follow-up of less than 4 years, 
there were significant differences in overall survival de-
pending on stage and the Charlson comorbidity index. 
Those authors concluded that patients with localized RCC 
and a Charlson comorbidity index greater than 2 did not 
gain a survival benefit from curative surgery. Kutikov et 
al. [9] reported that 5 year probabilities of kidney cancer 
death, other cancer death, and non-cancer death were 4%, 
7%, and 11% in 30,801 patients with localized, surgically 
treated RCC from the Surveillance, Epidemiology, and 
End Results (SEER) database. They identified that age 
was most predictive of non-kidney cancer deaths, and in-
creasing tumor size was inversely related to non-kidney 
cancer deaths. They estimated the risk of overall survival 
or non-kidney cancer death from various parameters in-
cluding race, gender, tumor size, and age; however, an im-
portant limitation of their study was a short follow-up du-
ration and a lack of data on the patients’ comorbidities [8,9], 
which may be one of the important parameters affecting life 
expectancy [10,11]. We believe that our study has an ad-
vantage over previous studies owing to the thorough analy-
sis of the clinical and pathological variables that could help 
in the choice of a proper treatment method and give more 
information about prognosis.
Consistent with our study, several studies demonstrated 
that overweight or obese patients with RCC have a more 
favorable prognosis than do patients with a low BMI 
[12-14]. However, the increased risk of death from other 
causes associated with a low BMI remains to be fully 
explained. The increased leptin and insulin-like growth 
factor-1 in obese patients might be associated with in-
creased survival [15]. Also, a low BMI might be an indicator 
of certain other chronic medical conditions or a low stand-Korean J Urol 2012;53:18-22
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ard of living, which could contribute to conditions such as 
undernutrition and may increase the risk of premature 
death [16,17]. 
This study had some important limitations. The retro-
spective nature of this study might have biased the sub-
sequent analysis. However, for ethical reasons, it does not 
seem reasonable to perform a clinical trial of this issue by 
randomly allocating the patients to active surveillance or 
surgical treatment. Also, longer follow-up data from this 
study population would be beneficial. Finally, individuals 
who did not undergo surgical management were excluded. 
Although the exact number and indications for surveil-
lance were not available, it is assumed that these patients 
were poor surgical candidates. Despite the limitations of 
this study, the usefulness of reviewing the cause of death 
of this relatively large series of patients with localized RCC 
is to build a foundation in the literature to support active 
surveillance for patients with old age or significant 
comorbidities.
CONCLUSIONS
The findings of our study suggest that old age, high ASA 
score, and low BMI are independent factors predicting 
death from other causes in patients with localized RCC. 
Other-cause-specific survival significantly differed on the 
basis of the number of risk factors for death from other 
causes. We conclude that the management of localized RCC 
should be individually based on predicted life expectancy 
considering these risk factors. Further studies will be re-
quired to evaluate the advisability of active surveillance in 
this patient population.
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